A Phase II Trial of Lapatinib and Trastuzumab in Patients with Heavily Pretreated Metastatic Breast Cancer
Phase 2
Recruiting
- Conditions
- HER2 positive breast cancer patients treted with multiple cytotoxic agent including trastuzumab
- Registration Number
- JPRN-UMIN000002651
- Lead Sponsor
- ational Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
a) Lapatinib pretreated b) Ejectoon fraction <50%
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method